Please find attached the Audited Standalone and Consolidated Financial Results for the financial year ended March 31, 2025

EBITDA margin compressionExceptional itemNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.0%Reaction day

₹27.26

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.7%+4.7% vs market

Specialty Chemicals peers, median of 84sector-2.5%+4.5% vs sector

On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 4.5 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.0-2.7+4.7-2.5+4.5

Next day

+3.9-2.7+6.6-2.6+6.5

+1.8-2.8+4.6-2.9+4.7

-0.2-4.9+4.7-4.8+4.6

-2.2-5.0+2.8-4.9+2.7

-1.0-3.6+2.7-4.5+3.5

-2.8-5.0+2.2-5.4+2.6

15d

+12.1+4.8+7.3+2.3+9.8

+16.8+5.6+11.2+2.2+14.6

+0.4+8.3-7.9+6.0-5.6

-4.6+8.8-13.4+6.4-11.0

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 84Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sudarshan Pharma Industries reported strong standalone revenue growth of ~36% to ₹22,535 lakhs in FY25 (vs ₹16,556 lakhs in FY24), driven by API manufacturing, job-work and chemicals trading. Consolidated revenue grew more modestly by ~5% to ₹27,726 lakhs. However, net profit declined ~12% on both standalone (₹995.86 lakhs vs ₹1,135.53 lakhs) and consolidated (₹1,003.10 lakhs vs ₹1,145.53 lakhs) bases, as rising costs compressed operating margins. The company booked ₹164.81 lakhs as an exceptional loss from waterlogging damage at its Bhiwandi warehouse, after the insurance claim of ₹281.73 lakhs was rejected. The promoter group was allotted 9 lakh convertible warrants (₹169.83 each, ~₹15.28 crore), and the company completed acquisitions of a Singapore subsidiary and 51% of Ishwari Healthcare. A ₹9.19 crore Dubai court award in its favour remains pending recovery.

Likely market impact

Mixed picture for shareholders — strong top-line growth signals business expansion, but contracting margins and falling profits may weigh on the stock in the short term. The promoter warrant allotment is confidence-boosting but will dilute equity if converted, and the rejected insurance claim and pending Dubai recovery add earnings uncertainty.

By the numbersConsolidated · Q4 FY25 vs Q4 FY24

	Q4 FY25	Q4 FY24	Change
Revenue	₹277.3 Cr	₹231.7 Cr	+19.6%
Operating profit	₹12.33 Cr	₹8.04 Cr	+53.3%
Profit after tax	—	—	—
EBITDA margin	—	—	—

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.